Close Menu

Liquid Biopsy

News and reporting on cell-free DNA testing.

The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 15 skipping alterations.

Foundation Medicine's liquid biopsy test will be used in the third stage of SCRUM-Japan, which focuses on advanced cancer patientsin Japan and other Asian countries.

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

A new analysis has provided evidence that adjuvant lung cancer immunotherapy benefits those with lingering ctDNA, but not necessary those without.

The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.